TLPPF - Lilly atopic dermatitis candidate lebrikizumab shows improvement in disease severity

A late-stage trial of Eli Lilly's (NYSE:LLY) lebrikizumab for atopic dermatitis showed significant improvement in measures of disease severity when combined with topical corticosteroids. After 16 weeks of treatment, 70% of patients with moderate-to-severe atopic dermatitis who received lebrikizumab along with topical corticosteroids achieved at least 75% improvement in overall disease severity. At 16 weeks, 41% of participants on lebrikizumab + topical corticosteroids achieved clear or almost clear skin compared to 22% of those taking placebo + topical corticosteroids. Those on lebrikizumab, an IL-13 inhibitor, also saw improvements in secondary endpoints such as skin clearance and itching, interference of itch on sleep, and quality of life compared to those on placebo. Australia-based Telix Pharmaceuticals (OTCPK:TLPPF) on Monday announced a licensing deal with Lilly (LLY) for the cancer biologic olaratumab.

For further details see:

Lilly atopic dermatitis candidate lebrikizumab shows improvement in disease severity